PAR
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR). (NCT01451541) | Sumitomo Pharma America, Inc. | 2011-10-01 |
| Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis (NCT01378429) | Sumitomo Pharma America, Inc. | 2011-07-01 |
Track PAR automatically
Every clearance here is in the API, with alerts when new ones post.